LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

Accueil・Liste d'Actions・Roivant Sciences Ltd

Roivant Sciences Ltd

Fermé

SecteurSoins de santé

28.58 2.69

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

27.83

Max

28.12

Chiffres clés
By Trading Economics
Revenu	-200M -314M
Ventes	428K 2M
Marge bénéficiaire	-15,692.896
Employés	750
EBITDA	-132M -290M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+22.36% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	5B 20B
Ouverture précédente	25.89
Clôture précédente	28.58

Sentiment de l'Actualité

By Acuity

67%

33%

310 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

11 / 11.18 Support & Résistance

Roivant Sciences Ltd Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 mai 2026, 23:43 UTC

Principaux Événements d'Actualité

New Zealand's Unemployment Rate Falls in 1Q

5 mai 2026, 23:20 UTC

Actions en Tendance

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mai 2026, 21:48 UTC

Résultats

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mai 2026, 21:05 UTC

Acquisitions, Fusions, Rachats

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mai 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mai 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mai 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5 mai 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mai 2026, 22:08 UTC

Résultats

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mai 2026, 22:07 UTC

Résultats

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:48 UTC

Résultats

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mai 2026, 21:48 UTC

Résultats

Pan American Silver 1Q Rev $1.2B >PAAS

5 mai 2026, 21:42 UTC

Résultats

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:38 UTC

Résultats

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:30 UTC

Résultats

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:29 UTC

Résultats

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:26 UTC

Résultats

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mai 2026, 21:25 UTC

Résultats

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mai 2026, 21:25 UTC

Résultats

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mai 2026, 21:24 UTC

Résultats

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:18 UTC

Résultats

Mistras Backs 2026 Rev $730M-$750M >MG

5 mai 2026, 21:17 UTC

Résultats

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mai 2026, 21:15 UTC

Résultats

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mai 2026, 21:12 UTC

Résultats

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mai 2026, 21:11 UTC

Résultats

SSR Mining 1Q Rev $581.8M >SSRM

5 mai 2026, 21:10 UTC

Résultats

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mai 2026, 21:10 UTC

Résultats

SSR Mining 1Q EPS $1.16 >SSRM

5 mai 2026, 21:08 UTC

Résultats

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:01 UTC

Résultats

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mai 2026, 21:01 UTC

Actions en Tendance

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparaison

Variation de prix

Roivant Sciences Ltd prévision

Objectif de Prix

By TipRanks

22.36% hausse

Prévisions sur 12 Mois

Moyen 34.7 USD 22.36%

Haut 41 USD

Bas 29 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

Achat

Maintien

Vente

Basé sur 10 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

11 / 11.18Support & Résistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

310 / 347Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.